EUVIMEDEUVIMED entdecken
Crossref

Neurological Performance and Clinical Outcomes Related to Patients With Oropouche‐Associated Guillain–Barré Syndrome

Frank D Martos-Benítez iD, Iliovanys Betancourt-Plaza, Isleidys Osorio-Carmenates, Nadieska J González-Martínez, Ileana Moráles-Suárez, Carilda E Peña-García, Yudeily L Pérez-Matos, Zurina Lestayo-O'Farrill, José R de Armas-Fernández, Raysa C Cárdenas-González, Judet Izquierdo-Castañeda, Ernesto Sánchez-de la Rosa und 1 weitere

Journal of the Peripheral Nervous System · 2025-03 · 30 (1)

DOI: 10.1111/jns.12683 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Peripheral Nervous System, online erschienen am 23.01.2025. Verfasst von Frank D Martos-Benítez und 12 weiteren Autor:innen. Beteiligte Einrichtung: Intensive Care Unit, National Institute of Neurology and Neurosurgery, Havana, Cuba. Hauptthemen laut MEDLINE: Guillain-Barre Syndrome, Bunyaviridae Infections. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims A recent study reported that Oropouche virus (OROV) infection may play a role in the etiology of Guillain–Barré syndrome. We aimed to identify the neurological performance, disease‐modifying therapies, and clinical outcomes related to patients with Oropouche‐associated Guillain–Barré syndrome admitted to the critical care unit.

Methods

This was an analysis of 210 patients diagnosed with Guillain–Barré syndrome and suspicion of Oropouche viral infection admitted to the critical care units from June 2024 to September 2024 using the national administrative healthcare data. OROV was identified by reverse‐transcriptase–polymerase‐chain‐reaction. Patients with Guillain–Barré syndrome and Oropouche infection were compared with those without Oropouche infection in terms of demography features, neurological performance, disease‐modifying therapies, and clinical outcomes.

Results

Most patients had a severe disease. Mechanical ventilation was required in 28.6%. Overall mortality rate was 14.3%. The median time from onset of weakness to intensive care unit discharge, and the median time from hospital admission to intensive care unit discharge was 18 days (IQR: 13–24.3 days) and 13 days (IQR: 9–19 days), respectively. Oropouche viral infection was detected in 43 (20.5%) patients. There were no differences among patients with and without Oropouche viral infection regarding general characteristics, neurological performance, disease‐modifying therapies, and outcomes. After adjusting for confounders in multivariate logistic regression analysis, Oropouche viral infection (OR: 1.94; 95% CI: 0.72–5.20; p = 0.189) was not related to increased mortality.

Interpretation

Oropouche viral infection does not modify the clinical course, disease severity, and outcomes of patients with Guillain–Barré syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Guillain-Barre SyndromeBunyaviridae InfectionsHumansMaleFemaleMiddle AgedAgedAdultIntensive Care UnitsRespiration, ArtificialRetrospective Studies

Stichwörter der Autor:innen

Guillain–Barré syndromeOROVOropouche feverdisabilitymuscular weaknessneuropathyradiculopathy

Autor:innen und Institutionen

  • Intensive Care Unit, National Institute of Neurology and Neurosurgery, Havana, Cuba.
  • National Department of Urgency, Emergency, and Transplant of the Ministry of Public Health, Havana, Cuba.
  • National Directorate of Hospitals of the Ministry of Public Health of Cuba, Havana, Cuba.
  • National Directorate of Science and Technological Innovation of the Ministry of Public Health, Havana, Cuba.
  • Viceministry of Hygiene, Epidemiology and Microbiology of the Ministry of Public Health, Havana, Cuba.
  • Intensive Care Unit, Provincial Clinical Surgical Teaching Hospital "Faustino Pérez", Matanzas, Cuba.

ORCID-Profile: Frank D Martos-Benítez

Zitieren

APA

Martos-Benítez, F. D., Betancourt-Plaza, I., Osorio-Carmenates, I., González-Martínez, N. J., Moráles-Suárez, I., Peña-García, C. E., Pérez-Matos, Y. L., Lestayo-O'Farrill, Z., de Armas-Fernández, J. R., Cárdenas-González, R. C., Izquierdo-Castañeda, J., la Rosa, E. S., & Orama-Requejo, V. (2025). Neurological Performance and Clinical Outcomes Related to Patients With Oropouche‐Associated Guillain–Barré Syndrome. Journal of the Peripheral Nervous System, 30(1). https://doi.org/10.1111/jns.12683

Vancouver

Martos-Benítez FD, Betancourt-Plaza I, Osorio-Carmenates I, González-Martínez NJ, Moráles-Suárez I, Peña-García CE, et al. Neurological Performance and Clinical Outcomes Related to Patients With Oropouche‐Associated Guillain–Barré Syndrome. Journal of the Peripheral Nervous System. 2025;30(1). doi:10.1111/jns.12683

BibTeX
@article{MartosBentez2025,
  author = {Martos-Benítez, Frank D and Betancourt-Plaza, Iliovanys and Osorio-Carmenates, Isleidys and González-Martínez, Nadieska J and Moráles-Suárez, Ileana and Peña-García, Carilda E and Pérez-Matos, Yudeily L and Lestayo-O'Farrill, Zurina and de Armas-Fernández, José R and Cárdenas-González, Raysa C and Izquierdo-Castañeda, Judet and la Rosa, Ernesto Sánchez-de and Orama-Requejo, Versis},
  title = {Neurological Performance and Clinical Outcomes Related to Patients With Oropouche‐Associated Guillain–Barré Syndrome},
  journal = {Journal of the Peripheral Nervous System},
  year = {2025},
  volume = {30},
  number = {1},
  doi = {10.1111/jns.12683}
}
Kostenlos starten →